Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline CEO Jean-Pierre Garnier called premature a prediction by Schering-Plough CEO Fred Hassan that FDA could approve a nasal-inhaled steroid for over-the-counter use this year
You may also be interested in...
Pediatric Growth Concerns Could Hold Corticosteroids Back A Grade
A reduction of growth rate found in children taking corticosteroids could be the biggest hurdle for sponsors seeking to switch the drugs to over-the-counter status
Pediatric Growth Concerns Could Hold Corticosteroids Back A Grade
A reduction of growth rate found in children taking corticosteroids could be the biggest hurdle for sponsors seeking to switch the drugs to over-the-counter status
Pediatric Growth Concerns Could Hold Corticosteroids Back A Grade
A reduction of growth rate found in children taking corticosteroids could be the biggest hurdle for sponsors seeking to switch the drugs to over-the-counter status